 Connection
Michael Bristow to Carbazoles
This is a "connection" page, showing publications Michael Bristow has written about Carbazoles.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.893 |
|
|
|
-
Bristow MR, Adams KF, Bauman JL, Feldman AM, Giles TD, Goldstein S, Mann DL, Talbert RL. The COMET trial. Congest Heart Fail. 2005 Jan-Feb; 11(1):39-47.
Score: 0.230
-
Pittenger B, Gill EA, Holcslaw TL, Bristow MR. Relation of dose of carvedilol to reduction in QT dispersion in patients with mild to moderate heart failure secondary to ischemic or to idiopathic dilated cardiomyopathy. Am J Cardiol. 2004 Dec 01; 94(11):1459-62.
Score: 0.229
-
Lowes BD, Tsvetkova T, Eichhorn EJ, Gilbert EM, Bristow MR. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol. 2001 Dec; 81(2-3):141-9.
Score: 0.186
-
Bristow MR. What type of beta-blocker should be used to treat chronic heart failure? Circulation. 2000 Aug 01; 102(5):484-6.
Score: 0.169
-
Lindenfeld J, Lowes BD, Bristow MR. Hypotension with dobutamine: beta-adrenergic antagonist selectivity at low doses of carvedilol. Ann Pharmacother. 1999 Dec; 33(12):1266-9.
Score: 0.162
-
Quaife RA, Christian PE, Gilbert EM, Datz FL, Volkman K, Bristow MR. Effects of carvedilol on right ventricular function in chronic heart failure. Am J Cardiol. 1998 Jan 15; 81(2):247-50.
Score: 0.142
-
Bristow MR, Abraham WT, Yoshikawa T, White M, Hattler BG, Crisman TS, Lowes BD, Robertson AD, Larrabee P, Gilbert EM. Second- and third-generation beta-blocking drugs in chronic heart failure. Cardiovasc Drugs Ther. 1997 May; 11 Suppl 1:291-6.
Score: 0.135
-
Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation. 1996 Dec 01; 94(11):2807-16.
Score: 0.131
-
Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, Larrabee P, Bristow MR. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996 Dec 01; 94(11):2817-25.
Score: 0.131
-
Quaife RA, Gilbert EM, Christian PE, Datz FL, Mealey PC, Volkman K, Olsen SL, Bristow MR. Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy. Am J Cardiol. 1996 Oct 01; 78(7):779-84.
Score: 0.130
-
Yoshikawa T, Port JD, Asano K, Chidiak P, Bouvier M, Dutcher D, Roden RL, Minobe W, Tremmel KD, Bristow MR. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J. 1996 Apr; 17 Suppl B:8-16.
Score: 0.125
-
Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol. 1995 May; 25(6):1225-31.
Score: 0.118
-
Bristow MR, Larrabee P, M?ller-Beckmann B, Minobe W, Roden R, Skerl L, Klein J, Handwerger D, Port JD. Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes. Clin Investig. 1992; 70 Suppl 1:S105-13.
Score: 0.093
-
Bristow MR, Larrabee P, Minobe W, Roden R, Skerl L, Klein J, Handwerger D, Port JD, M?ller-Beckmann B. Receptor pharmacology of carvedilol in the human heart. J Cardiovasc Pharmacol. 1992; 19 Suppl 1:S68-80.
Score: 0.093
-
MacGregor JF, Wachter SB, Munger M, Stoddard G, Bristow MR, Gilbert EM. Carvedilol produces sustained long-term benefits: follow-up at 12 years. Congest Heart Fail. 2009 Jan-Feb; 15(1):5-8.
Score: 0.076
-
Bullinga JR, Alharethi R, Schram MS, Bristow MR, Gilbert EM. Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure. J Card Fail. 2005 Dec; 11(9):693-9.
Score: 0.061
-
Bristow MR, Feldman AM, Adams KF, Goldstein S. Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial? J Card Fail. 2003 Dec; 9(6):444-53.
Score: 0.053
-
Abraham WT, Gilbert EM, Lowes BD, Minobe WA, Larrabee P, Roden RL, Dutcher D, Sederberg J, Lindenfeld JA, Wolfel EE, Shakar SF, Ferguson D, Volkman K, Linseman JV, Quaife RA, Robertson AD, Bristow MR. Coordinate changes in Myosin heavy chain isoform gene expression are selectively associated with alterations in dilated cardiomyopathy phenotype. Mol Med. 2002 Nov; 8(11):750-60.
Score: 0.050
-
Metra M, Nodari S, D'Aloia A, Muneretto C, Robertson AD, Bristow MR, Dei Cas L. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol. 2002 Oct 02; 40(7):1248-58.
Score: 0.049
-
Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P, Ferguson D, Wolfel EE, Lindenfeld J, Tsvetkova T, Robertson AD, Quaife RA, Bristow MR. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med. 2002 May 02; 346(18):1357-65.
Score: 0.048
-
Lindenfeld J, Robertson AD, Lowes BD, Bristow MR. Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers. J Am Coll Cardiol. 2001 Dec; 38(7):1950-6.
Score: 0.046
-
Port JD, Bristow MR. beta-Adrenergic receptors, transgenic mice, and pharmacological model systems. Mol Pharmacol. 2001 Oct; 60(4):629-31.
Score: 0.046
-
Yancy CW, Fowler MB, Colucci WS, Gilbert EM, Bristow MR, Cohn JN, Lukas MA, Young ST, Packer M. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med. 2001 May 03; 344(18):1358-65.
Score: 0.045
-
Fowler MB, Vera-Llonch M, Oster G, Bristow MR, Cohn JN, Colucci WS, Gilbert EM, Lukas MA, Lacey MJ, Richner R, Young ST, Packer M. Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group. J Am Coll Cardiol. 2001 May; 37(6):1692-9.
Score: 0.045
-
Schleman KA, Lindenfeld JA, Lowes BD, Bristow MR, Ferguson D, Wolfel EE, Abraham WT, Zisman LS. Predicting response to carvedilol for the treatment of heart failure: a multivariate retrospective analysis. J Card Fail. 2001 Mar; 7(1):4-12.
Score: 0.044
-
Bristow MR. beta-adrenergic receptor blockade in chronic heart failure. Circulation. 2000 Feb 08; 101(5):558-69.
Score: 0.041
-
Lowes BD, Gill EA, Abraham WT, Larrain JR, Robertson AD, Bristow MR, Gilbert EM. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol. 1999 Apr 15; 83(8):1201-5.
Score: 0.039
-
Bristow MR, Roden RL, Lowes BD, Gilbert EM, Eichhorn EJ. The role of third-generation beta-blocking agents in chronic heart failure. Clin Cardiol. 1998 Dec; 21(12 Suppl 1):I3-13.
Score: 0.038
-
Cohn JN, Fowler MB, Bristow MR, Colucci WS, Gilbert EM, Kinhal V, Krueger SK, Lejemtel T, Narahara KA, Packer M, Young ST, Holcslaw TL, Lukas MA. Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group. J Card Fail. 1997 Sep; 3(3):173-9.
Score: 0.035
-
Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas MA. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation. 1996 Dec 01; 94(11):2800-6.
Score: 0.033
-
Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996 May 23; 334(21):1349-55.
Score: 0.032
-
Sucharov CC, Langer S, Bristow M, Leinwand L. Shuttling of HDAC5 in H9C2 cells regulates YY1 function through CaMKIV/PKD and PP2A. Am J Physiol Cell Physiol. 2006 Nov; 291(5):C1029-37.
Score: 0.016
-
Asano K, Zisman LS, Yoshikawa T, Headley V, Bristow MR, Port JD. Bucindolol, a nonselective beta 1- and beta 2-adrenergic receptor antagonist, decreases beta-adrenergic receptor density in cultured embryonic chick cardiac myocyte membranes. J Cardiovasc Pharmacol. 2001 Jun; 37(6):678-91.
Score: 0.011
-
Noori A, Lindenfeld J, Wolfel E, Ferguson D, Bristow MR, Lowes BD. Beta-blockade in adriamycin-induced cardiomyopathy. J Card Fail. 2000 Jun; 6(2):115-9.
Score: 0.010
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|